FINWIRES · TerminalLIVE
FINWIRES

$GSK

43 stories mentioning GSKUpdated 23h ago

Every FINWIRES story that references GSK, newest first.

Wire

GSK's ViiV Healthcare Highlights New Long-Acting Injectable Data on Cabenuva in HIV Treatment

GSK's (GSK) majority-owned ViiV Healthcare unit reported trial data that back Cabenuva's, also known as cabotegravir plus rilpivirine, potential as a long-acting injectable HIV treatment, according to a Wednesday statement.The LATA trial's week 96 results demonstrated Cabenuva's superiority over daily oral therapy in 476 virologically suppressed adolescents of ages 12 to 19 years with HIV in certain African countries, GSK said. Meanwhile, data from the US-based OPERA cohort showed that Cabenuva maintained virologic suppression comparable with daily oral therapy in 6,800 adults with HIV, GSK added.GSK also said six-month follow-up data from the phase 1 CLARITY trial supported a "more favorable" injection experience with long-acting cabotegravir, compared with lenacapavir, after a single dose.The company is also investigating an intramuscular formulation of cabotegravir dosed three times a year for HIV prevention, with data to be presented at a future medical event, according to the statement.Price: $53.05, Change: $-0.66, Percent Change: -1.24%

$GSK
Sectors

Sector Update: Healthcare Stocks Gain Late Afternoon

Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index rising 2.3% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 2.4%.The iShares Biotechnology ETF (IBB) was up 0.8%.In corporate news, Iqvia (IQV) shares surged 13% after it reported a year-over-year increase in Q2 adjusted earnings and revenue. The company also raised its 2026 outlook.GSK (GSK) shares advanced 3.3% after it posted higher Q2 core earnings and sales that also beat analysts' estimates. Separately, GSK licensor Hansoh's phase 3 trial of risvutatug rezetecan to treat osteosarcoma, the most common primary bone cancer, achieved its primary endpoint in progression-free survival, GSK said Tuesday.Seer (SEER) shareholders Bradley Radoff and Michael Torok said Tuesday they have submitted their fourth non-binding proposal to buy the company, raising their offer to $2.55 per share in cash. Seer shares jumped past 9%.Zimmer Biomet (ZBH) shares climbed 3.7% after UBS upgraded the stock to buy from sell, and raised the price target to $115 from $89.

$GSK$IQV$SEER$ZBH
Sectors

Sector Update: Healthcare Stocks Gain in Afternoon Trading

Healthcare stocks rose Tuesday afternoon, with the NYSE Healthcare Index adding 2.2% and the State Street Health Care Select Sector SPDR ETF (XLV) rising 2.3%.The iShares Biotechnology ETF (IBB) was up 0.8%.In corporate news, GSK (GSK) shares gained 3.9% after the firm posted higher Q2 core earnings and sales that also beat analysts' estimates. Separately, GSK licensor Hansoh's phase 3 trial of risvutatug rezetecan to treat osteosarcoma, the most common primary bone cancer, achieved its primary endpoint in progression-free survival, GSK said Tuesday.Seer (SEER) shareholders Bradley Radoff and Michael Torok said Tuesday they have submitted their fourth non-binding proposal to buy the company, raising their offer to $2.55 per share in cash. Seer shares jumped past 5%.Iqvia (IQV) shares surged 12% after it reported higher Q2 adjusted earnings and revenue, and raised its 2026 outlook.

$GSK$IQV$SEER
Sectors

Sector Update: Healthcare

Healthcare stocks rose Tuesday afternoon, with the NYSE Healthcare Index adding 2.2% and the State Street Health Care Select Sector SPDR ETF (XLV) rising 2.3%.The iShares Biotechnology ETF (IBB) was up 0.8%.In corporate news, GSK (GSK) shares gained 3.8% after it posted higher Q2 core earnings and sales that also beat analysts' estimates. Separately, GSK licensor Hansoh's phase 3 trial of risvutatug rezetecan to treat osteosarcoma, the most common primary bone cancer, achieved its primary endpoint in progression-free survival, GSK said Tuesday.

$GSK
Wire

GSK Licensor's Late-Stage China Study for Risvutatug Rezetecan in Bone Cancer Meets Primary Endpoint

GSK (GSK) licensor Hansoh's phase 3 trial of risvutatug rezetecan in osteosarcoma, the most common primary bone cancer, achieved its primary endpoint in progression-free survival, GSK said Tuesday.The trial, which was conducted in China in patients with osteosarcoma who have progressed or relapsed after receiving at least two prior lines of systemic therapy, showed that the therapy led to a statistically significant improvement in progression-free survival compared with chemotherapy, according to the statement.Hansoh also reported consistent benefit across secondary endpoints like overall survival, GSK added.Safety profile was consistent with previous findings in the same tumor type, with no new safety signals identified, the company said. Hansoh will use the trial data for regulatory submissions in China, GSK said.Price: $53.96, Change: $+1.98, Percent Change: +3.80%

$GSK
Asia Markets

European Equities Traded in US as ADRs Ease in Tuesday Trading

European equities traded in the US as American depositary receipts eased late Tuesday morning with the S&P Europe Select ADR Index down 0.1% to 1,903.66.From continental Europe, the gainers were led by consumer goods company Unilever (UL) and software firm SAP (SAP), which climbed 8.6% and 4.8%, respectively. They were followed by pharmaceutical company Sanofi (SNY) and brewing company Anheuser-Busch InBev (BUD), which advanced 3.7% and 3%, respectively.The decliners from continental Europe were led by telecommunications operator Nokia (NOK) and biopharmaceutical company DBV Technologies (DBVT), which dropped 6.3% and 5.1%, respectively. They were followed by medical device maker EDAP TMS (FOCL) and semiconductor company Sequans Communications (SQNS), which lost 3.3% and 3.1%, respectively.The gainers from the UK were led by biotech firm Trinity Biotech (TRIB) and software company Endava (DAVA), which rose 9.6% and 7.9%, respectively. They were followed by pharmaceutical company GSK (GSK) and communications company WPP (WPP), which were up 6.5% and 6.4%, respectively.The decliners from the UK and Ireland were led by pharmaceutical company Silence Therapeutics (SLN) and lender Barclays (BCS), which fell 7.8% and 7.3%, respectively. They were followed by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and lender Lloyds Banking Group (LYG), which dropped 7% and 2.5%, respectively.

$BCS$BDRX$BUD$DAVA$DBVT$FOCL$GSK$LYG$NOK$SAP$SLN$SNY$SQNS$TRIB$UL$WPP
Sectors

Sector Update: Healthcare Stocks Flat to Higher Pre-Bell Tuesday

Healthcare stocks were flat to higher pre-bell Tuesday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) up 1.2%.GSK (GSK) shares were up more than 2% after the company posted higher Q2 core earnings and sales.IQVIA (IQV) stock was up more than 11% after the company reported higher Q2 adjusted earnings and revenue, and raised its 2026 outlook.Centene (CNC) shares were down more than 5% even after the company reported that it swung to Q2 adjusted earnings as revenue increased during the period. Centene also lifted its 2026 guidance.

$CNC$GSK$IBB$IQV$XLV
Sectors

Sector Update: Healthcare

Healthcare stocks were flat to higher pre-bell Tuesday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) up 1.3%.GSK (GSK) shares were up more than 1% after the company posted higher Q2 core earnings and sales.

$GSK
Sectors

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks declined late Wednesday afternoon, with the NYSE Healthcare Index down 0.4% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.5%.The iShares Biotechnology ETF (IBB) fell 0.9%.In corporate news, Repligen (RGEN) has agreed to acquire BioLife Solutions (BLFS) in a deal valued at about $1.5 billion, the companies said. Repligen shares climbed 2.3%, and BioLife jumped past 6%.Amgen (AMGN) has agreed to pay $74 million to settle a shareholder lawsuit alleging the company waited too long to disclose it may owe the Internal Revenue Service $10.7 billion in back taxes, penalties and interest, news outlets reported Tuesday. Amgen shares were down 0.1%.Arrowhead Pharmaceuticals (ARWR) shares surged past 20% after the company said its phase 3 clinical studies of plozasiran to treat hypertriglyceridemia met the primary endpoint of triglyceride reduction compared with placebo.GSK (GSK) shares were fractionally higher after it said Wednesday the US Food and Drug Administration has approved Jideytro, a ROS1-selective inhibitor, to treat adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer who have previously received a ROS1 kinase inhibitor.

$AMGN$ARWR$BLFS$GSK$RGEN
Wire

GSK Gets FDA Approval for Jideytro in Previously Treated ROS1-Positive Lung Cancer

GSK (GSK) said Wednesday the US Food and Drug Administration has approved Jideytro, a ROS1-selective inhibitor, to treat adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer who have previously received a ROS1 kinase inhibitor.The approval, based on the phase I/II Arros-1 trial, comes ahead of the original Sept. 18 target action date after the FDA granted Jideytro Breakthrough Therapy and Orphan Drug designations.The therapy aims to combine high target-selectivity, broad coverage of ROS1 resistance mutations, and blood-brain barrier penetration to address disease in the brain, the company added.Jideytro is GSK's first approved medicine in lung cancer.Price: $50.93, Change: $+0.15, Percent Change: +0.30%

$GSK
Sectors

Sector Update: Healthcare Stocks Mixed Late Afternoon

Healthcare stocks were mixed late Friday afternoon, with the NYSE Healthcare Index unchanged and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.3%.The iShares Biotechnology ETF (IBB) was up 0.1%.In corporate news, Eli Lilly's (LLY) long-term GLP-1 franchise is unlikely to face significant pressure from generic GLP-1 drugs, as manufacturing constraints should limit generic market penetration while the company's next-generation therapies are expected to preserve its market leadership, UBS Securities said in a note. Lilly shares were up 0.7%.Intuitive Surgical (ISRG) shares fell nearly 14%. Growth in the company's da Vinci robotic surgery procedures in the US moderated due in part to changes in Affordable Care Act premium subsidies, even as it reported better-than-expected quarterly results.GSK (GSK) shares were down 2.1% after it said Friday it will discontinue development of camlipixant for refractory chronic cough after the drug produced mixed results in the phase 3 CALM-1 and CALM-2 trials.Xencor (XNCR) shares jumped about 13% after the firm said Friday that phase 1 results for its experimental cancer therapy XmAb819 in advanced clear cell renal cell carcinoma have been selected for a proffered paper oral presentation at the European Society of Medical Oncology Congress in October.

$GSK$ISRG$LLY$XNCR
Sectors

Sector Update: Healthcare Stocks Mixed in Afternoon Trading

Healthcare stocks were mixed Friday afternoon, with the NYSE Healthcare Index increasing 0.1% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.3%.The iShares Biotechnology ETF (IBB) was up 0.1%.In corporate news, Intuitive Surgical (ISRG) shares fell past 12%. Growth in the company's da Vinci robotic surgery procedures in the US moderated due in part to changes in Affordable Care Act premium subsidies, even as it reported better-than-expected quarterly results.GSK (GSK) shares were down 2.7% after it said Friday it will discontinue development of camlipixant for refractory chronic cough after the drug produced mixed results in the phase 3 CALM-1 and CALM-2 trials.Takeda Pharmaceutical (TAK) shares rose 2%. The company said late Thursday that new phase 3 data showed its oral TYK2 inhibitor, zasocitinib, delivered high rates of skin clearance across difficult-to-treat body sites in adults with moderate-to-severe plaque psoriasis.

$GSK$ISRG$TAK
Asia Markets

European Equities Traded in the US as American Depositary Receipts Decline Friday

European equities traded in the US as American depositary receipts were lower on Friday morning, shedding 0.6% to 1,899.52 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by energy companies Equinor (EQNR) and Eni (E), which climbed 4.1% and 3.1% respectively.They were followed by biotech companies Genenta Science (GNTA) and DBV Technologies (DBVT), which added 3% and 2.2%.The decliners from continental Europe were led by tech company Nokia (NOK), which dropped 3%, and semiconductor companies STMicroelectronics (STM) and ASML (ASML), which fell 2.6% each.They were followed by software company SAP (SAP), which shed 1.8%.From the UK and Ireland, the gainers were led by pharmaceutical company Compass Pathways (CMPS), which climbed 4.8%, and energy companies Shell (SHEL) and BP (BP), which added 2.3% and 1.4% respectively.The decliners from the UK and Ireland were led by budget airline Ryanair (RYAAY) and pharmaceutical company GSK (GSK), which lost 3.6% and 2.8% respectively. They were followed by bank Barclays (BCS), which shed 2.1%.

$ASML$BCS$BP$CMPS$DBVT$E$EQNR$GNTA$GSK$NOK$RYAAY$SAP$SHEL$STM
Sectors

Sector Update: Healthcare Stocks Mixed Premarket Friday

Healthcare stocks were mixed premarket Friday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.4% and the iShares Biotechnology ETF (IBB) 0.7% lower.GSK (GSK) shares were down more than 3% after the company said it will discontinue development of camlipixant for refractory chronic cough after the drug produced mixed results in the phase 3 CALM-1 and CALM-2 trials.Novartis (NVS) shares were up more than 1% after the company said the US Food and Drug Administration approved Fabhalta under the traditional approval pathway to slow kidney function decline in adults with primary immunoglobulin A nephropathy at risk of disease progression.Takeda Pharmaceutical (TAK) shares were 0.6% higher after the company said new phase 3 data showed its oral TYK2 inhibitor, zasocitinib, delivered high rates of skin clearance across difficult-to-treat body sites in adults with moderate-to-severe plaque psoriasis.

$GSK$IBB$NVS$TAK$XLV
Commodities

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday as Investors Retreat From Chipmaker Stocks

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.7%, and the actively traded Invesco QQQ Trust (QQQ) fell 1.8% in Friday's premarket activity, as investors continued to pull back from chipmakers.US stock futures were also lower, with S&P 500 Index futures down 0.8%, Dow Jones Industrial Average futures slipping 0.5%, and Nasdaq futures declining 1.6% before the start of regular trading.June housing starts jumped by 19% from the previous month to a 1.427 million annual rate, above expectations compiled by Bloomberg as of 7:30 am ET for a 1.310 million rate after a decrease to a 1.199 million pace in May.US import prices rose by 0.3% in June, compared to the 0.7% decrease expected in a survey compiled by Bloomberg and following a 1.7% increase in May.Industrial production data for June will be released at 9:15 am ET, followed by the preliminary University of Michigan consumer sentiment reading for July at 10:00 am ET.In premarket action, bitcoin was down by 1.5%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 1.7% lower, Ether ETF (EETH) retreated 2%, and Bitcoin & Ether Market Cap Weight ETF (BETH) gained 1.3%.Power Play:ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was down 0.6%, the Vanguard Consumer Staples Index Fund ETF Shares (VDC) was up 0.7%, and the iShares US Consumer Staples ETF (IYK) advanced 0.9%. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) lost 0.7%. The VanEck Retail ETF (RTH) gained 1%, while the State Street SPDR S&P Retail ETF (XRT) was 0.5% lower.XPeng (XPEV) shares were down more than 5% pre-bell after closing the prior session with a 1% rise. The Wall Street Journal reported Thursday that the company is launching its L03 SUV in Munich, marking its first global vehicle launch outside China as it expands in Europe and other overseas markets.Winners and Losers:TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) retreated 2.2%, and the iShares US Technology ETF (IYW) was 2.1% lower, while the iShares Expanded Tech Sector ETF (IGM) was down 2.1%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) declined 3.4%, while the iShares Semiconductor ETF (SOXX) fell by 3.9%.Cadence Design Systems (CDNS) shares were down more than 5% in premarket activity following a 1.8% fall at the prior close. The company said it will work with logic semiconductor manufacturer Rapidus to advance "agentic AI" for advanced-node system-on-chip design under a new collaboration.IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) retreated 0.6%, while the Vanguard Industrials Index Fund (VIS) and the iShares US Industrials ETF (IYJ) were flat.SpaceX's (SPCX) stock was down more than 4% before the opening bell after CEO Elon Musk said in a Thursday post on X that the company's Starship rocket triggered an "automatic launch abort," with the next launch to be rescheduled possibly "in a few days".Health CareThe State Street Health Care Select Sector SPDR ETF (XLV) advanced 0.4%, the Vanguard Health Care Index Fund (VHT) was up 0.1%, while the iShares US Healthcare ETF (IYH) slipped 0.5%. The iShares Biotechnology ETF (IBB) was down 0.4%.GSK (GSK) stock was down more than 2% premarket after the company said it would discontinue development of camlipixant for refractory chronic cough after the drug produced mixed results in the phase 3 CALM-1 and CALM-2 trials.EnergyThe iShares US Energy ETF (IYE) was up 0.6%, while the State Street Energy Select Sector SPDR ETF (XLE) was 1.5% higher.BP (BP) stock was up more than 1%, and ConocoPhillips (COP) was 2% higher before market open. CNBC reported Friday that the companies plan to reveal billions of dollars in new investments in Iraq to help build its energy sector and increase resilience against Iranian disruptions.FinancialThe State Street Financial Select Sector SPDR ETF (XLF) advanced 0.1%. Direxion Daily Financial Bull 3X Shares (FAS) was up 0.2%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was 0.1% lower.Truist Financial (TFC) shares traded down 1% in early hours activity, even after the company reported higher Q2 earnings and revenue.CommoditiesFront-month US West Texas Intermediate crude oil advanced by 2.7% to $81.04 per barrel on the New York Mercantile Exchange. Natural gas was up by 0.5% to $2.87 per 1 million British Thermal Units. The United States Oil Fund (USO) was up 2.4%, while the United States Natural Gas Fund (UNG) was 1% lower.Gold futures for July retreated 0.1% to $3,988.00 an ounce on the Comex. Silver futures were down 1.1% to $55.59 an ounce. SPDR Gold Shares (GLD) decreased 0.2%, and the iShares Silver Trust (SLV) was 0.9% lower.

Dow JonesNasdaq CompositeS&P 500$BETH$BITO$BP$CDNS$COP$EEM$EETH$EXI$FAS$FAZ$GLD$GSK$IBB$IGM$IGV$IPK$IVV$IWM$IYE$IYH$IYJ$IYK$IYW$PMR$QQQ$RTH$SLV$SOXX$SPCX$SPY$TFC$UNG$USO$VDC$VHT$VIS$XLE$XLF$XLI$XLK$XLP$XLV$XLY$XPEV$XRT$XSD
Sectors

Sector Update: Healthcare

Healthcare stocks were mixed premarket Friday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.3% and the iShares Biotechnology ETF (IBB) 0.6% lower.GSK (GSK) shares were down more than 2% after the company said it will discontinue development of camlipixant for refractory chronic cough after the drug produced mixed results in the phase 3 CALM-1 and CALM-2 trials.

$GSK
Wire

GSK Licensor Hansoh Reports Positive Phase 3 Results for Risvutatug Rezetecan in China

GSK (GSK) said Friday its licensor, Hansoh Pharmaceutical, reported the phase 3 Artemis-008 trial of risvutatug rezetecan met its primary overall survival endpoint in Chinese patients with advanced or relapsed small-cell lung cancer.The study showed statistically significant and clinically meaningful improvements in overall survival versus topotecan, with benefits also observed across key secondary endpoints, including progression-free survival.The results mark the first positive phase 3 overall survival data for a B7-H3-targeted antibody-drug conjugate in any tumor type and support the continued global development of Ris-Rez outside Greater China, GSK said.GSK shares were up 1% in Friday premarket trading.

$GSK
Sectors

Sector Update: Healthcare Stocks Lean Lower Pre-Bell Wednesday

Healthcare stocks were leaning lower premarket Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 0.1% and the iShares Biotechnology ETF (IBB) declining by 0.6%.Astrazeneca (AZN) and Daiichi Sankyo are in advanced talks with England's drug pricing regulator to make the breast cancer medicine Enhertu available to certain patients, Bloomberg reported, citing people familiar with the negotiations. Shares of Astrazeneca were down more than 1% pre-bell.GSK (GSK) agreed to expand its exclusive strategic collaboration with Sino Biopharmaceutical's Chia Tai Tianqing Pharmaceutical Group subsidiary to include rights to commercialize two GSK respiratory therapies in mainland China, Sino said in a filing. GSK stock was down more than 1% premarket.Seres Therapeutics (MCRB) shares were up more than 2% after the company said top-line results from a phase 1 clinical trial of SER-155 to treat patients with immune checkpoint inhibitor-related enterocolitis met its primary endpoint.

$AZN$GSK$IBB$MCRB$XLV
Wire

GSK Unit Launches Tender Offer for Nuvalent Acquisition

GSK (GSK) said Wednesday its Harmony Row Acquisition unit commenced a tender offer to purchase all outstanding Class A and Class B shares of Nuvalent (NUVL) for $124 per share in cash.Following the consummation of the offer, the unit will merge into Nuvalent, which will continue as a direct wholly-owned subsidiary of GlaxoSmithKline LLC.Nuvalent's board of directors recommended that stockholders accept the offer and tender their shares, GSK said.The tender offer and withdrawal rights will expire on July 14, the company added.Price: $51.20, Change: $-0.87, Percent Change: -1.67%

$GSK$NUVL
Wire

GSK, Spero Therapeutics Get FDA Approval for Utebzi in Complicated Urinary Tract Infections

GSK (GSK) and Spero Therapeutics (SPRO) said Wednesday that the US Food and Drug Administration has approved Utebzi as treatment for complicated urinary tract infections, including pyelonephritis, in adults.Utebzi, or tebipenem pivoxil, is the first and only oral carbapenem antibiotic approved in the US and is expected to become available by the end of 2026, the companies said.The approval was based on phase 3 trial data showing Utebzi's non-inferiority to intravenous imipenem-cilastatin, with tebipenem pivoxil achieving an overall success rate of 58.5% against 60.2% for imipenem-cilastatin, according to a statement. Tebipenem pivoxil's safety profile is also "generally similar" to that of imipenem-cilastatin, the companies said.GSK shares were up about 1%, while Spero stock was down more than 14% in Wednesday trading.Price: $52.72, Change: $+0.50, Percent Change: +0.96%

$GSK$SPRO

Showing 1-20 of 43

Track with the FINWIRES app suite